

BLISS GVS PHARMA LTD.



May 03, 2025

To The Manager, Listing Department National Stock Exchange of India Limited Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Script Code: 506197
---	---

Dear Sir/Madam,

Subject: Intimation under Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Bliss GVS Pharma Limited (hereinafter referred to as "**the Company**") had invoked arbitration proceedings against Pan Pharmaceuticals Limited (Nairobi, Kenya) for recovery of its outstanding dues by way of filing a petition seeking appointment of an arbitrator before the Supreme Court of India.

The details required to be disclosed under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as **Annexure-A**.

Kindly take the same on your record.

Thanking you,
For **Bliss GVS Pharma Limited**

Aditi Bhatt
Company Secretary

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

ANNEXURE - A

Details required to be disclosed under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. no.	Particulars	Description
1.	Brief Details of Litigation	
A.	Name of the Opposing Party	Pan Pharmaceuticals Limited (Nairobi, Kenya)
B.	Court/ tribunal/agency where litigation is filed	Supreme Court of India under Arbitration and Conciliation Act, 1996
C.	Brief details of dispute/litigation	The Company had invoked arbitration proceedings against Pan Pharmaceuticals Limited for recovery of its outstanding dues.
2.	Expected financial implications, if any, due to compensation, penalty etc.	The expected recovery arising from the aforementioned arbitration proceedings is estimated at USD 1.69 million. Furthermore, the Company has proactively made appropriate provisions in its books of accounts for the amount recoverable from Pan Pharmaceuticals Limited, thereby ensuring minimal or no adverse financial impact.
3.	Quantum of claims, if any;	The quantum of claim will depend upon the outcome of the arbitrating authority.

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Palghar, Dist. Thane - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com